The Life Sciences team advised bluebird bio (Nasdaq: BLUE) on the pricing of its underwritten public offering of 9,090,910 shares of its common stock at a public offering price of $55.00 per share, before underwriting discounts. bluebird bio has granted the underwriters a 30-day option to purchase up to an additional 1,363,636 shares of common stock. All of the shares in the offering are to be sold by bluebird bio. The company anticipates the total gross proceeds from the offering (before deducting underwriters’ discounts and commissions and estimated offering expenses) will be approximately $500 million, excluding any exercise of the underwriters’ option to purchase additional shares. Goldman Sachs & Co. LLC, BofA Securities and Cowen acted as joint book-running managers of the offering.
Headquartered in Cambridge, Massachusetts, bluebird bio is pioneering gene therapy with purpose. The company is developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. bluebird works positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit. The company also operates in Seattle, Washington, Durham, North Carolina and Zug, Switzerland.
The Goodwin team was led by Michael Bison, Gregg Katz, Yasin Akbari, Kathryn Weston and Sonia Wu.
For additional details on the offering, please read the press release.